NO20013757D0 - Kjernetablett for kontrollert frigivelse av glicazid etter oral administrasjon - Google Patents

Kjernetablett for kontrollert frigivelse av glicazid etter oral administrasjon

Info

Publication number
NO20013757D0
NO20013757D0 NO20013757A NO20013757A NO20013757D0 NO 20013757 D0 NO20013757 D0 NO 20013757D0 NO 20013757 A NO20013757 A NO 20013757A NO 20013757 A NO20013757 A NO 20013757A NO 20013757 D0 NO20013757 D0 NO 20013757D0
Authority
NO
Norway
Prior art keywords
glicazide
oral administration
controlled release
core tablet
tablet
Prior art date
Application number
NO20013757A
Other languages
English (en)
Other versions
NO20013757L (no
NO329951B1 (no
Inventor
Bruno Huet De Barochez
Patrick Wuthrich
Louis Martin
Original Assignee
Adir
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9541429&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20013757(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Adir filed Critical Adir
Publication of NO20013757D0 publication Critical patent/NO20013757D0/no
Publication of NO20013757L publication Critical patent/NO20013757L/no
Publication of NO329951B1 publication Critical patent/NO329951B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
NO20013757A 1999-02-01 2001-07-31 Kjernetablett for kontrollert frigivelse av gliclazid etter oral administrasjon. NO329951B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9901082A FR2788981B1 (fr) 1999-02-01 1999-02-01 Comprime matriciel permettant la liberation prolongee de gliclazide apres administration par voie orale
PCT/FR1999/002520 WO2000018373A1 (fr) 1999-02-01 1999-10-15 Comprime matriciel permettant la liberation prolongee de gliclazide apres administration par voie orale

Publications (3)

Publication Number Publication Date
NO20013757D0 true NO20013757D0 (no) 2001-07-31
NO20013757L NO20013757L (no) 2001-08-09
NO329951B1 NO329951B1 (no) 2011-01-31

Family

ID=9541429

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20013757A NO329951B1 (no) 1999-02-01 2001-07-31 Kjernetablett for kontrollert frigivelse av gliclazid etter oral administrasjon.

Country Status (37)

Country Link
US (1) US6733782B1 (no)
EP (1) EP1148871B1 (no)
JP (2) JP4716465B2 (no)
KR (1) KR100491600B1 (no)
CN (1) CN1160061C (no)
AP (1) AP1243A (no)
AT (1) ATE296621T1 (no)
AU (1) AU764516B2 (no)
BR (1) BR9917012A (no)
CA (1) CA2273420C (no)
CZ (1) CZ298196B6 (no)
DE (1) DE69925639T2 (no)
DK (1) DK1148871T3 (no)
EA (1) EA002625B1 (no)
EE (1) EE05024B1 (no)
ES (1) ES2241323T3 (no)
FR (1) FR2788981B1 (no)
GE (1) GEP20053501B (no)
HK (1) HK1043049A1 (no)
HR (1) HRP20010632B1 (no)
HU (1) HU225693B1 (no)
ID (1) ID30225A (no)
IL (2) IL144246A0 (no)
ME (1) ME00436B (no)
NO (1) NO329951B1 (no)
NZ (1) NZ512878A (no)
OA (1) OA11756A (no)
PL (1) PL194505B1 (no)
PT (1) PT1148871E (no)
RS (1) RS50121B (no)
SA (1) SA00210446B1 (no)
SK (1) SK285209B6 (no)
TR (1) TR200102002T2 (no)
UA (1) UA68414C2 (no)
WO (1) WO2000018373A1 (no)
YU (1) YU53101A (no)
ZA (1) ZA200106305B (no)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AP1243A (en) * 1999-02-01 2004-02-02 Servier Lab Core tablet for controlled release of gliclazide after oral administration.
SE0200539D0 (sv) * 2002-02-25 2002-02-25 Metcon Medicin Ab Granulation process and starch granulate
CN100391459C (zh) * 2003-05-26 2008-06-04 沈阳药科大学 甲磺酸多沙唑嗪缓释制剂
CN1294908C (zh) * 2003-06-08 2007-01-17 安徽省医药科技实业公司 口服格列齐特缓释制剂
CA2563325C (en) * 2004-04-29 2010-06-22 Lotus Pharmaceutical Co., Ltd. Oral modified-release lozenges and their preparation method
CN100413491C (zh) * 2004-06-14 2008-08-27 北京德众万全药物技术开发有限公司 一种难溶性药物的控释制剂
EP1827453A1 (en) * 2004-12-06 2007-09-05 Themis Laboratories Private Limited Sulfonylurea compositions and a process for its preparation
US9029427B2 (en) 2005-11-11 2015-05-12 Asahi Kasei Chemicals Corporation Controlled release solid preparation
US20080286343A1 (en) * 2007-05-16 2008-11-20 Dzenana Cengic Solid form
TR200704897A1 (tr) * 2007-07-13 2009-02-23 Sanovel �La� Sanay� Ve T�Caret Anon�M ��Rket� Uzatılmış salım sağlayan gliklazid formülasyonları@
TR200708938A2 (tr) * 2007-12-26 2008-11-21 Ali̇ Rai̇f İlaç Sanayi̇ Ve Ti̇caret A.Ş. Uzatılmış salım sağlayan gliklazid tablet
ITFI20080016A1 (it) * 2008-02-05 2009-08-06 Valpharma Sa Formulazioni farmaceutiche orali contenenti gliclazide.
FR2928836B1 (fr) * 2008-03-21 2011-08-26 Servier Lab Forme galenique secable permettant une liberation modifiee du principe actif
WO2009140279A2 (en) * 2008-05-12 2009-11-19 Concert Pharmaceuticals, Inc. Sulfonyl urea compounds
EP2181705A1 (en) 2008-10-31 2010-05-05 Disphar International B.V. Sustained-release formulation of gliclazide
CN102341099A (zh) * 2009-03-03 2012-02-01 什诺波特有限公司 R-巴氯芬前药的持续释放口服剂型
MX339452B (es) 2010-06-16 2016-05-27 Teijin Pharma Ltd Tableta con nucleo recubierto de liberacion controlada.
TR201107482A1 (tr) 2010-12-21 2012-07-23 Sanovel İlaç San.Ve Ti̇c.A.Ş. Vildagliptin ve gliklazidin iki tabakalı kombinasyon kompozisyonu.
EP2468268B1 (en) 2010-12-21 2017-12-13 Sanovel Ilaç Sanayi Ve Ticaret Anonim Sirketi Combination composition of vildagliptin and gliclazide
TR201103946A1 (tr) 2011-04-22 2012-11-21 Sanovel İlaç Sanayi̇ Ve Ti̇caret Anoni̇m Şi̇rketi̇ Kontrollü salım sağlayan gliklazid formülasyonları.
JO3283B1 (ar) 2011-04-26 2018-09-16 Sanofi Sa تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI)
US20150031737A1 (en) * 2012-02-24 2015-01-29 Ranbaxy Laboratories Limited Stabilized controlled-release pharmaceutical composition comprising gliclazide
WO2014128116A1 (en) * 2013-02-19 2014-08-28 Sanovel Ilac Sanayi Ve Ticaret A.S. A production process for gliclazide formulations
ITFI20130184A1 (it) 2013-08-01 2015-02-02 Valpharma Internat S P A Una formulazione farmaceutica di gliclazide a rilascio modificato, somministrabile per via orale, e suo metodo di produzione.
ITMI20132065A1 (it) * 2013-12-11 2015-06-12 Farmatron Ltd Sistemi terapeutici a rilascio modificato per la somministrazione orale di curcumina nel trattamento delle malattie intestinali
AU2015289124B2 (en) 2014-07-18 2021-03-11 Sanofi Method for predicting the outcome of a treatment with aflibercept of a patient suspected to suffer from a cancer
WO2016042568A1 (en) * 2014-09-16 2016-03-24 Suresh Pareek Extended release formulation of gliclazide
CN111329841B (zh) * 2020-03-04 2021-11-19 山东鲁抗医药集团赛特有限责任公司 格列齐特缓释片及其制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1449404A (en) * 1973-03-30 1976-09-15 Science Union & Cie N-arylsulphonyl urea derivatives
US4056623A (en) * 1975-03-05 1977-11-01 Science Union Et Cie, Societe Francaise De Recherche Medicale Methods of treating animals suffering from hyperlipidemia using certain N-phenyl sulphonyl-N'-(3-azabicycloalkyl) ureas
US5057321A (en) * 1990-06-13 1991-10-15 Alza Corporation Dosage form comprising drug and maltodextrin
IT1246188B (it) * 1990-07-27 1994-11-16 Resa Farma Procedimento per la preparazione di composizioni farmaceutiche aventi aumentata velocita' di dissoluzione della sostanza attiva e composizioni ottenute.
DE4336159A1 (de) * 1993-10-22 1995-04-27 Kurt Heinz Prof Dr Bauer Hochwirksame, den Wirkstoff schnell oder kontrolliert freisetzende Zubereitungsformen von Sulfonylharnstoffen und Verfahren zu deren Herstellung
US6056977A (en) * 1997-10-15 2000-05-02 Edward Mendell Co., Inc. Once-a-day controlled release sulfonylurea formulation
AP1243A (en) * 1999-02-01 2004-02-02 Servier Lab Core tablet for controlled release of gliclazide after oral administration.

Also Published As

Publication number Publication date
PL356707A1 (en) 2004-06-28
CA2273420A1 (fr) 2000-08-01
EA002625B1 (ru) 2002-06-27
OA11756A (en) 2005-07-19
DE69925639D1 (de) 2005-07-07
IL144246A (en) 2006-12-10
EP1148871B1 (fr) 2005-06-01
UA68414C2 (en) 2004-08-16
HUP0105365A3 (en) 2002-11-28
SK285209B6 (sk) 2006-08-03
CN1342068A (zh) 2002-03-27
ATE296621T1 (de) 2005-06-15
HU225693B1 (en) 2007-06-28
KR100491600B1 (ko) 2005-05-27
AU764516B2 (en) 2003-08-21
RS50121B (sr) 2009-03-25
ES2241323T3 (es) 2005-10-16
EP1148871A1 (fr) 2001-10-31
KR20010093307A (ko) 2001-10-27
EA200100827A1 (ru) 2002-02-28
FR2788981A1 (fr) 2000-08-04
YU53101A (sh) 2004-05-12
ID30225A (id) 2001-11-15
NO20013757L (no) 2001-08-09
NZ512878A (en) 2002-05-31
SK10952001A3 (sk) 2001-12-03
US6733782B1 (en) 2004-05-11
AP1243A (en) 2004-02-02
PT1148871E (pt) 2005-08-31
SA00210446B1 (ar) 2006-10-11
EE05024B1 (et) 2008-06-16
BR9917012A (pt) 2002-04-16
JP2002525310A (ja) 2002-08-13
AP2001002212A0 (en) 2001-09-30
EE200100398A (et) 2002-10-15
GEP20053501B (en) 2005-05-10
IL144246A0 (en) 2002-05-23
AU6098299A (en) 2000-04-17
PL194505B1 (pl) 2007-06-29
JP4716465B2 (ja) 2011-07-06
ZA200106305B (en) 2002-07-31
TR200102002T2 (tr) 2002-01-21
WO2000018373A1 (fr) 2000-04-06
DE69925639T2 (de) 2006-04-27
CN1160061C (zh) 2004-08-04
FR2788981B1 (fr) 2002-05-17
NO329951B1 (no) 2011-01-31
HRP20010632A2 (en) 2005-02-28
DK1148871T3 (da) 2005-09-19
HK1043049A1 (en) 2002-09-06
JP2008179649A (ja) 2008-08-07
CA2273420C (fr) 2002-07-09
HUP0105365A2 (hu) 2002-04-29
CZ20012661A3 (cs) 2001-11-14
ME00436B (me) 2011-10-10
CZ298196B6 (cs) 2007-07-18
HRP20010632B1 (en) 2006-02-28

Similar Documents

Publication Publication Date Title
NO20013757L (no) Kjernetablett for kontrollert frigivelse av glicazid etter oral administrasjon
EE200000383A (et) Peroraalne farmatseutiline pikendatud vabanemisega annusvorm
DE69941115D1 (de) Tablette mit einzelnem kern zur oralen verabreichung mit kontrollierter freisetzung
NO20014035D0 (no) System for oral administrasjon av medikament
DE60100186D1 (de) Orale pharmazeutische formulierungen von benzimidazolderivaten und verfahren zu ihrer herstellung
NO995753D0 (no) Gastroretarderende mikrosfaerer med styrt frigivelse for bedret administrasjon av medikament
ITMI991316A0 (it) Composizioni farmaceutiche orali a rilascio modificato di mesalazina
IL145581A0 (en) A modified release pharmaceutical composition comprising amoxycillin
PT1110543E (pt) Composicao de libertacao prolongada para administracao oral
EE9900441A (et) Farmatseutiline kompositsioon N-piperidino-3-pürasoolkarboksamiidi derivaadi, tema soolade ja nende solvaatide suu kaudu manustamiseks
NO20020976D0 (no) Retarderte, orale, farmasöytiske administreringsformer
HUP0401714A3 (en) Oral dosage form for propiverine or its pharmaceutically acceptable salts with an extended release of the active ingredient
AU3574500A (en) Rapidly disintegrable tablet for oral administration
FI4823U1 (fi) Muunnetulla tavalla vapauttava lääkeformulaatio
ATE296622T1 (de) Trimetazidinhaltige matrixtablette zur verlängerten wirkstofffreisetzung nach oraler gabe
NO20014738L (no) Tolperisonholdig farmasöytisk preparat for oral administrering
AU2001287977A1 (en) Controlled release formulations for oral administration
EP1207852A4 (en) ORAL PHARMACEUTICALS WITH TAXED RELEASE FOR ORAL ADMINISTRATION
FI20000780A (fi) Peroraalinen lääkemuoto lääkeaineen hallituksi vapauttamiseksi
HUP0201667A3 (en) Oral form of administration
NO20021452D0 (no) Orale kontrollerte frigivelsesformuleringer
EP1188440A4 (en) MEDICINAL COMPOSITION FOR ORAL ADMINISTRATION
EG22658A (en) Matrix tablet enabling prolonged release of gliclazide after administration by the oral route
NO20003284D0 (no) Farmasøytisk preparat for oral administrering
DE10081277D2 (de) Kapsel mit kontrollierter Wirkstofffreisetzung

Legal Events

Date Code Title Description
MK1K Patent expired